A Yardstick for Managing Patients with Atopic Dermatitis
|
|
- Alison Wood
- 6 years ago
- Views:
Transcription
1 AAIFNA 2018 Symposium A Yardstick for Managing Patients with Atopic Dermatitis Mark Boguniewicz, MD Professor, Division of Allergy-Immunology Department of Pediatrics National Jewish Health and University of Colorado School of Medicine
2 Disclosures Research Grants: NIH/NIAID, Anacor, Regeneron Consultant/Advisory Board: Regeneron, Sanofi-Genzyme, Pfizer Content will include discussion of offlabel uses of medications for atopic dermatitis
3 Learning Objectives At the conclusion of this presentation, participants should be able to: 1. Apply knowledge of the pathophysiology of AD to the selection of treatment options 2. Manage patients with AD in accordance with the latest treatment guidelines and expert recommendations
4 Practice Parameter Update: Flow chart of the diagnosis and management of AD Often still reactive therapy J Allergy Clin Immunol 2013;131:295 Non-recommended & non-approved systemic therapies
5 Global variations in prevalence of eczema symptoms in children from ISAAC Phase 3 Developed and developing countries Lancet 1998;351:1225; Odhiambo JA, et al. J Allergy Clin Immunol 2009;124
6 Characterization of different courses of atopic dermatitis in adolescent and adult patients >40% of patients with onset of AD before age 6 years will persist into adulthood Garmhausen D, et al. Allergy 2013;68:
7 Persistence of mild to moderate AD Cross-sectional & cohort study of a long-term registry of children with AD enrolled in PEER* 7157 pts enrolled in PEER with at least 2 yrs of f/u for 4248 and at least 5 yrs of f/u for 2416 At every age (2-26 yrs), >80% of PEER participants had symptoms of AD and/or were using medication to treat their AD It was not until age 20 yrs that 50% of pts had at least 1 lifetime 6-mo symptom- and treatment-free period Margolis JS, et al. JAMA Dermatol 2014;150:593 *Pediatric Eczema Elective Registry; ~ 16% of PEER subset with FLG mutations
8 US prevalence: adults 2010 and 2012 National Health Interview Survey data of US adults y Nationally representative cohort from all 50 states (n=27,157 and 34,613) 1-year prevalence was 10.2% (less specific question) and 7.2% (more specific question) 1-year prevalence of eczema with asthma or hay fever 3.2% 16 US AD PREVALENCE (%) Children: 12.0% ( %) Adults: 7.2% ( %) AGE (YR) Silverberg JI. Dermatol Clin 2017;35;283-9
9 Adult onset/recurrence of AD 54% with onset of AD after the age of 18 years AD n=6931 TNS household panel (n=60,000) Hanifin JM, Reed MI. Associations of childhood eczema severity: A US population based study. Dermatitis : 82-91
10 Clinical relevance Adult onset / recurrent AD is more common than previously recognized Important to rule out the differen;al diagnosis
11 Atopic dermatitis: a (systemic) disease of altered skin barrier and immune dysregulation Non-lesional Irritants Boguniewicz M, Leung DY. Immunol Rev 2011;242:233 >30% asthma, allergies & nonatopic co-morbidities
12 Association between adult atopic dermatitis, cardiovascular disease, and increased heart attacks in three population-based studies Data from NHANES (n = 4970) and NHIS 2010 & 2012 (n = 27, 157 & 34, 525) NHANES, flexural eczema in past yr associated with significantly higher odds of CAD (P 0.04), heart attack (P 0.01) and congestive heart failure (P 0.02) NHIS 2010 & 2012, 1-yr history of eczema associated with significantly higher odds of CAD (P 0.02), angina (P 0.02), heart attack (P 0.047), other heart disease (P < ), stroke (P 0.02), and PVD (<0.0001) Adults with AD may have increased cardiovascular disease, heart attack, and stroke Allergy 2015;70:1300
13 Atopic dermatitis is associated with an increased risk for rheumatoid arthritis and inflammatory bowel disease, and a decreased risk for type 1 diabetes German National Health Insurance cohort aged 40 years or younger (n = 655,815) from Pts with AD (n = 49,847) at increased risk for incident RA (risk ratio [RR], 1.72; 95% CI, ) and/or IBD (CD: RR, 1.34; 95% CI, ; UC: RR, 1.25; 95% CI, ). After adjusting for health care utilization, there was a nominally significant inverse effect on T1D risk (RR, 0.72; 95% CI, ) No disproportionate occurrence of known RA, IBD, or T1D risk alleles in AD AD is a risk factor for development of RA and IBD. This excess comorbidity cannot be attributed to major known IBD and RA genetic risk factors Schmitt J, et al. J Allergy Clin Immunol 2016;137:130
14 Fig 1. Flow chart of the diagnosis and management of AD Differential diagnosis J Allergy Clin Immunol 2013;131:295
15 Differential diagnosis of AD Congenital disorders Netherton's syndrome Chronic dermatoses Seborrheic dermatitis Contact dermatitis (allergic or irritant) Nummular eczema Lichen simplex chronicus Infections and infestations Scabies HIV-associated dermatitis Malignancy Cutaneous T cell lymphoma (mycosis fungoides/sézary syndrome) Boguniewicz M, Leung DY. Middleton s Allergy 2014 Immunodeficiencies Wiskott-Aldrich syndrome SCID Hyper-IgE syndrome DOCK8 mutations IPEX Metabolic disorders Zinc deficiency Pyridoxine (vitamin B 6 ) and niacin deficiency Multiple carboxylase deficiency Phenylketonuria Proliferative disorder Letterer-Siwe disease
16 A pragmatic approach to patch testing atopic dermatitis patients: Clinical recommendations based on expert consensus opinion * *e.g. head/neck predominance, hand or foot, eyelid, perioral Chen JK, et al. Dermatitis 2016;27:186
17 Differential diagnosis of AD Congenital disorders Netherton's syndrome Chronic dermatoses Seborrheic dermatitis Contact dermatitis (allergic or irritant) Nummular eczema Lichen simplex chronicus Infections and infestations Scabies HIV-associated dermatitis Malignancy Cutaneous T cell lymphoma (mycosis fungoides/sézary syndrome) Boguniewicz M, Leung DY. Middleton s Allergy 2014 Immunodeficiencies Wiskott-Aldrich syndrome SCID Hyper-IgE syndrome DOCK8 mutations IPEX Metabolic disorders Zinc deficiency Pyridoxine (vitamin B 6 ) and niacin deficiency Multiple carboxylase deficiency Phenylketonuria Proliferative disorder Letterer-Siwe disease
18 Mycosis fungoides happens The most common form of CTCL Epidermotropic neoplasm of CD4+ T cells Robert C, Kupper TS. N Engl J Med 1999;341:1817
19 Moving beyond the Practice Parameter and Guidelines Topical PDE4 inhibitor J Allergy Clin Immunol 2013;131:295 MoAb vs IL-4 receptor alpha
20 The role of phosphodiesterase 4 inhibition in the pathophysiology of atopic dermatitis Guttman-Yassky E, et al. Br J Dermatol 2018 (submitted)
21 Crisaborole: targeting PDE4 Zane LT, et al. Immunotherapy 2016;8:853-66
22 Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis in children and adults To assess the efficacy and safety of crisaborole ointment, a PDE4 inhibitor in 2 phase III AD studies 2 identical VC, DB studies randomly assigned (2:1, crisaborole:vehicle) pts aged 2 yrs or older with an Investigator s Static Global Assessment (ISGA) score of mild or moderate for 2x/d application for 28 days Primary end point was ISGA score at day 29 of clear (0)/ almost clear (1) with 2-grade or greater improvement from baseline Paller AS, et al. J Am Acad Dermatol 2016;75: e4
23 More crisaborole- than vehicle-treated patients achieved ISGA score success (clear/almost clear with 2-grade improvement; AD-301: 32.8% vs 25.4%, P =.038; AD-302: 31.4% vs 18.0%, P<.001), with a greater percentage with clear/almost clear (51.7% vs 40.6%, P =.005; 48.5% vs 29.7%, P <.001) Crisaborole-treated patients achieved success in ISGA score and improvement in pruritus earlier than those treated with vehicle (both P.001) Treatment-related adverse events were infrequent and mild to moderate in severity Paller AS, et al. J Am Acad Dermatol 2016;75: e4
24 Crisaborole Improves ISGA at Day 29 Phase 3 Primary Outcome Baseline Characteris5cs Primary End Point Age groups (%) 2 6 yrs 7 11 yrs yrs 18 yrs Baseline ISGA (%) Mild (2) Moderate (3) Crisaborole (n = 503) AD- 301 Vehicle (n = 256) Crisaborole (n = 513) AD- 302 Vehicle (n = 250) PaQents achieving success at Day 29 (%)* P = P < % BSA Mean Range n = 503 n = 256 n = 513 n = 250 AD- 301 AD- 302 Crisaborole Vehicle * ISGA of 0 [clear] or 1 [almost clear] with 2 grade improvement from baseline. Paller AS, et al. J Am Acad Dermatol. 2016;75(3):
25 Crisaborole Improves Pruritus in Mild-to- Moderate AD Phase 3 Predefined Outcome A greater proporqon of crisaborole- treated paqents achieved improvement in pruritus across all study visits Median Qme to improvement = 1.37 days acqve vs 1.73 days control (P = 0.001) PaQents achieving improvement in pruritus (%)* * Score of 0 or 1 with 1 grade reducqon from baseline. Paller AS, et al. J Am Acad Dermatol. 2016;75(3): P < P < P < P = Baseline Day 8 Day 15 Day 22 Day 29 Crisaborole Vehicle 48 53
26 More crisaborole- than vehicle-treated patients achieved ISGA score success (clear/almost clear with 2-grade improvement; AD-301: 32.8% vs 25.4%, P =.038; AD-302: 31.4% vs 18.0%, P<.001), with a greater percentage with clear/almost clear (51.7% vs 40.6%, P =.005; 48.5% vs 29.7%, P <.001) Crisaborole-treated patients achieved success in ISGA score and improvement in pruritus earlier than those treated with vehicle (both P.001) Treatment-related adverse events were infrequent and mild to moderate in severity Crisaborole ointment 2% approved by FDA in Dec 2016 for treatment of mildmoderate AD in patients 2 years and older Paller AS, et al. J Am Acad Dermatol 2016;75: e4
27 Dupilumab, a fully human monoclonal Ab against IL-4 receptor alpha inhibits signaling of IL-4 & IL-13 Type I Receptor B cells, T cells, Monocytes, Eosinophils, Fibroblasts Type II Receptor Epithelial cells, Smooth muscle cells, Fibroblasts, Monocytes, Activated B cells
28 Two phase 3 trials of dupilumab vs placebo in atopic dermatitis 2 randomized, placebo-controlled, phase 3 trials of identical design (SOLO 1, n=671 and SOLO 2, n=708) Adults with moderate-to-severe AD (IGA 3-4) inadequately controlled by topical treatment randomly assigned in a 1:1:1 ratio to receive for 16 wks subcutaneous dupilumab (300 mg) or placebo weekly or dupilumab 300 mg qo wk alternating with placebo* Primary outcome was proportion of patients with IGA score of 0 or 1 (clear or almost clear) and reduction of 2 points in that score from baseline at week 16 *patients treated with dupilumab received 600 mg loading dose Simpson EL, et al. N Engl J Med 2016;375:
29 Demographic and clinical characteristics of patients at baseline Simpson EL, et al. N Engl J Med 2016;375:
30 Simpson EL, et al. N Engl J Med 2016;375: Efficacy outcomes
31 SOLO 1 & SOLO 2: 1 & key 2 end points Simpson EL, et al. N Engl J Med 2016;375: P<0.001 for all dupilumab vs placebo
32 SOLO 1 & SOLO 2: 2 end points Simpson EL, et al. N Engl J Med 2016;375: P<0.001 for all dupilumab vs placebo
33 Simpson EL, et al. N Engl J Med 2016;375: Adverse events
34 Adverse events For the 16 wk treatment period, overall rate of AEs (65-73% dupilumab vs 65-72% placebo) comparable between dupilumab and placebo groups Proportion of pts who completed treatment period was 88-94% for dupilumab and % for placebo Rate of serious AEs was 1-3% for dupilumab and 5-6% for placebo Serious and severe infections were numerically higher in placebo groups in both studies (0.5-1% dupilumab and 2-3% placebo) AEs noted to have higher rate with dupilumab treatment across both studies included injection site reactions (10-20% dupilumab; 7-8% placebo) and conjunctivitis (7-12% dupilumab; 2% placebo) approximately 26% of pts in both studies reported history of allergic conjunctivitis at study entry No patient discontinued therapy due to injection site reactions and only 1 patient discontinued therapy due to conjunctivitis Dupilumab approved by FDA on Mar 28, 2017 for the treatment of adult patients with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable
35 Lancet 2017;389:2287
36 Dupilumab + TCS efficacy at week 16 and week 52: CHRONOS Phase 3 results PaQents achieving IGA of 0 or 1 and 2 points Improvement from BL (Primary End Point) EASI- 75 (Key Secondary End Point) * P < vs placebo + TCS * P < vs placebo + TCS * PaQents (%) * * * * * * * Placebo qwk + TCS Dupilumab 300 mg q2wks + TCS Dupilumab 300 mg qwk + TCS Significant improvement in pruritus as early as Week 2 and sustained to Week 52 Co- primary end point in the EU and Japan Blauvelt A, et al. Lancet 2017; 389:
37 Chronos: EASI 50 & 75 over 52 weeks Blauvelt A, et al. Lancet 2017;389:2287
38 Dupilumab: Safety at 52 Weeks Event, n (%) Placebo qwk + TCS (n = 315) Dupilumab 300 mg q2wks + TCS (n = 110) Dupilumab 300 mg qwk + TCS (n = 315) 1 AE 226 (84) 97 (88) 261 (83) 1 SAE 16 (5) 4 (4) 9 (3) Death 0 0 1* (< 1) AEs leading to treatment disconqnuaqon 24 (8) 2 (2) 9 (3) AEs occurring in 5% of paqents Nasopharyngi;s 61 (19) 25 (23) 60 (19) URTI 32 (10) 11 (10) 43 (14) AD 144 (46) 20 (18) 52 (17) Injec;on site reac;on 24 (8) 16 (15) 60 (19) Asthma 19 (6) 5 (5) 2 (1) Herpes infec;ons 25 (8) 8 (7) 22 (7) Non- herpe;c skin infec;ons 56 (18) 12 (11) 26 (8) Conjuc;vi;s 25 (8) 15 (14) 61 (19) * Motor vehicle accident not considered related to study drug. Blauvelt A, et al. AAD 2017; Orlando, FL. Abstract 5267.
39 Br J Dermatol 2017; Nov 28 [Epub ahead of print]
40 CAFÉ study design To evaluate efficacy and safety of dupilumab with concomitant TCS in adults with AD with inadequate response to/intolerance of CsA or for whom CsA was medically inadvisable 16 wk, double-blind, randomized, placebo-controlled phase 3 trial with pts randomized 1:1:1 to subq dupilumab 300 mg qw:q2w:placebo All received concomitant medium-potency TCS from wk 2 through wk 16; dosage could be tapered if lesions cleared or stopped for adverse reactions to TCS de Bruin-Weller M, et al Br J Dermatol 2017; Nov 28 [Epub ahead of print]
41 CAFÉ results 325 pts randomized and 318 completed trial Significantly more pts on dupilumab qw+tcs/q2w+tcs achieved 75% improvement from baseline in EASI at wk 16 vs placebo+tcs (1 endpoint) (59.1%/62.6% vs 29.6%; P< vs placebo+tcs, both doses) Dupilumab qw+tcs/q2w+tcs significantly improved pruritus, pain, sleep disturbance, symptoms of anxiety and depression, and QOL Treatment groups had ~ overall rates of adverse events (69.1%/72.0%/69.4%; qw+tcs/q2w+tcs/placebo+tcs) and serious adverse events (1.8%/1.9%/1.9%) Conjunctivitis more frequent with dupilumab+tcs; skin infections more frequent with placebo+tcs de Bruin-Weller M, et al Br J Dermatol 2017; Nov 28 [Epub ahead of print]
42 CAFÉ Conclusions Dupilumab+TCS significantly improved signs and symptoms of AD and QOL in adults with history of inadequate response to/intolerance of CsA, or for whom CsA treatment was medically inadvisable No new safety signals were identified de Bruin-Weller M, et al Br J Dermatol 2017; Nov 28 [Epub ahead of print]
43 Dupilumab trials in adolescents & children with AD Study to determine safety and tolerability of dupilumab in patients aged 6 to <18 years with atopic dermatitis - Canada, Europe (NCT ) - completed Study to assess long-term safety of dupilumab administered in patients 6 to <18 years of age with atopic dermatitis Canada, Europe (NCT ) - ongoing FDA approval for pediatric dupilumab trials in US: Efficacy and safety of dupilumab in patients 12 to <18 years of age with moderate-to-severe atopic dermatitis (NCT ) enrollment complete Study to determine safety and tolerability of dupilumab in patients aged 6 to 11 years with atopic dermatitis Fitzpatrick s Dermatology in Gen Med 2012;170
44 Molecular changes in AD transcriptome Beck LA, et al. N Engl J Med 2014;371:130
45 Targeting pruritus H4R antagonist ZPL (oral) Phase 2a NK1R antagonists (oral) VLY-686/tradipitant Serlopitant TPRV1 Channel Antagonist PAC (cream) Paller AS, et al. J Allergy Clin Immunol 2017;140:
46
47 Boguniewicz M. J Allergy Clin Immunol Pract 2017;5:1477 Boguniewicz M, et al. J Allergy Clin Immunol Pract 2017;5:1519
48 Complex pathophysiology of atopic dermatitis and selected targets of biologics *IL-17 *IL-22 *IL-4Rα * *IL-13 *IL-31R *IL-12/ IL-23p40 Boguniewicz M. J Allergy Clin Immunol Pract 2017;5:1477
49 Atopic Dermatitis Yardstick: Practical recommendations for an evolving therapeutic landscape Boguniewicz M, et al. Ann Allergy Clin Immunol 2018;120:10 1 Indicated for patients with mild-to-moderate AD, ages 2 years and older ; 2 Indicated for patients with moderate-to-severe AD, ages 18 years and older; 3 Not FDA-approved to treat AD ; 4 FDA approved to treat AD, but not recommended for long-term maintenance
50 Atopic Dermatitis Yardstick: Practical recommendations for an evolving therapeutic landscape Boguniewicz M, et al. Ann Allergy Clin Immunol 2018;120:10
51 Atopic Dermatitis Yardstick: Practical recommendations for an evolving therapeutic landscape Boguniewicz M, et al. Ann Allergy Clin Immunol 2018;120:10
52 Atopic Dermatitis Yardstick: Practical recommendations for an evolving therapeutic landscape Boguniewicz M, et al. Ann Allergy Clin Immunol 2018;120:10
53 AD pts from phase 2 & 3 trials pre-/post-dupilumab Photos courtesy of Dr E Guttman-Yassky Boguniewicz M, et al. Ann Allergy Clin Immunol 2018;120:10
54 Atopic Dermatitis Program A multidisciplinary team approach
55 NIAID Atopic Dermatitis Research Network
Positioning New Treatments for Atopic Dermatitis in Our Practice Parameter
40 th Annual Pulmonary and Allergy Update Positioning New Treatments for Atopic Dermatitis in Our Practice Parameter Mark Boguniewicz, MD Professor, Division of Allergy-Immunology Department of Pediatrics
More informationUniversity Medical Center Utrecht, Utrecht, Netherlands; 2 University of Lübeck, Lübeck, Germany; 3
Dupilumab With Concomitant Topical Corticosteroids in Adult Patients With Atopic Dermatitis who are not Adequately Controlled With or are Intolerant to Cyclosporine A, or When This Treatment is Medically
More informationAn Update on Topical Therapy for Atopic Dermatitis
An Update on Topical Therapy for Atopic Dermatitis Amy S. Paller, M.D. Professor and Chair of Dermatology Professor of Pediatrics Northwestern University Feinberg School of Medicine Chicago, Illinois Disclosures
More informationAtopic Dermatitis: Emerging therapies. Melinda Gooderham MSc MD FRCPC
Atopic Dermatitis: Emerging therapies Melinda Gooderham MSc MD FRCPC SKiN Centre for Dermatology, Peterborough Assistant Professor, Queen s University, Kingston ON Investigator, Probity Medical Research,
More informationLearning Objectives 10/26/2017. New Treatments in Atopic Dermatitis
New Treatments in Atopic Dermatitis Lynda C. Schneider, MD Professor of Pediatrics, Harvard Medical School Boston Children s Hospital lynda.schneider@childrens.harvard.edu Disclosures: Lynda Schneider,
More informationThe Burden of Atopic Dermatitis: from Population to Bedside
The Burden of Atopic Dermatitis: from Population to Bedside S028 AAD Annual Meeting March 2, 2019 Research and institutional funding Sanofi Regeneron Disclosures Consultant Honoraria Sanofi Astellas Canada
More informationOverview. Atopic Dermatitis. Overview. 1. Genes and pathogenesis 2. Natural history and disease course 3. Comorbidities 4. Treatments 5.
Overview Atopic Dermatitis Albert C. Yan, MD, FAAP, FAAD Children s Hospital of Philadelphia Perelman School of Medicine at the University of Pennsylvania 1. Genes and pathogenesis 2. Natural history and
More informationThe Role of Allergen Immunotherapy and Biologicals in the Treatment of Atopic Dermatitis
The Role of Allergen Immunotherapy and Biologicals in the Treatment of Atopic Dermatitis John Oppenheimer MD Div Allergy and Immunology UMDNJ-Rutgers Potential Conflicts of Interest Consultant GSK, Teva,
More informationAssessing the Current Treatment of Atopic Dermatitis: Unmet Needs
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationBiologic Therapies for Atopic Dermatitis and Beyond
Biologic Therapies for Atopic Dermatitis and Beyond Jonathan Corren, M.D. Departments of Medicine and Pediatrics, David Geffen School of Medicine at UCLA Disclosures Genentech - research Medimmune/AZ -
More informationPNW EPC Drug Effectiveness Review Project Summary Report Atopic Dermatitis New Drug Evaluation: Dupilumab
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationPNW EPC Drug Effectiveness Review Project Summary Report Atopic Dermatitis New Drug Evaluation: Dupilumab
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationLawrence F. Eichenfield, M.D.
What s New in Pediatric Dermatology Lawrence F. Eichenfield, M.D. Professor of Dermatology and Pediatrics Rady Children s Hospital, San Diego University of California, San Diego Disclosure Lawrence F.
More informationCENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August
BRAND NAME Dupixent GENERIC NAME dupilumab MANUFACTURER Regeneron DATE OF APPROVAL March 28, 2017 PRODUCT LAUNCH DATE First week of April 2017 REVIEW TYPE Review type 1 (RT1): New Drug Review Full review
More informationLessons Learned from the International Eczema Council (IEC)
Lessons Learned from the International Eczema Council (IEC) Amy S. Paller, MD Northwestern University Feinberg School of Medicine American Academy of Dermatology meeting F046 February 17, 2017 No conflicts
More informationWhat s New in Atopic Dermatitis?
What s New in Atopic Dermatitis? SMITA AWASTHI, MD ASSISTANT CLINICAL PROFESSOR, DEPT. OF DERMATOLOGY AND PEDIATRICS UNIVERSITY OF CALIFORNIA, DAVIS Disclosures No financial disclosures relevant to this
More informationAtopic Dermatitis Guidelines: What s New?
Atopic Dermatitis Guidelines: What s New? Lawrence F. Eichenfield, M.D. Professor of Dermatology and Pediatrics University of California, San Diego Rady Children s Hospital, San Diego Anacor/Pfizer Genentech
More informationWhat s Topical About Topicals?
What s Topical About Topicals? Megha M. Tollefson, MD Associate Professor of Dermatology and Pediatrics July 29, 2017 2015 MFMER 3513105-1 Disclosures None 2015 MFMER 3513105-2 Outline Topical steroids
More informationUPDATES IN ATOPIC DERMATITIS
UPDATES IN ATOPIC DERMATITIS Amanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute, Scottsdale, AZ LEARNING OBJECTIVES Discuss epidemiology, risk factors, and causes of
More informationUpdates. Updates. Crisaborole 2% Ointment. New Therapies! 9/14/17. Dermatology Update 2017 Pediatric Dermatology NEW THERAPIES. July July 2017
Dermatology Update 2017 Pediatric Dermatology Melinda Jen, MD Director of Dermatologic Surgery Director of Pigmented Lesion Clinic Assistant Professor of Pediatrics and Dermatology Children s Hospital
More informationDupilumab and Crisaborole for Atopic Dermatitis: Effectiveness and Value. Public Meeting May 25, 2017
Dupilumab and Crisaborole for Atopic Dermatitis: Effectiveness and Value Public Meeting May 25, 2017 Welcome and Introduction Midwest Comparative Effectiveness Public Advisory Council (CEPAC) The Institute
More informationMarch 9, 2015 From: The Pediatric Dermatology Research Alliance (PeDRA)
Web: www.pedraresearch.org From: The Pediatric Dermatology Research Alliance (PeDRA) To: Jennifer Shepherd, Center for Drug Evaluation and Research Food and Drug Administration, 10903 New Hampshire Ave.,
More informationManagement of Chronic Idiopathic Urticaria
9/3/216 Management of Chronic Idiopathic Urticaria Brian Berman, M.D., Ph.D. Professor Emeritus of Dermatology and Dermatologic Surgery, University of Miami Co-Director Center for Clinical and Cosmetic
More informationUpdate on systemic therapies and emerging treatments How do I choose a systemic agent?
Update on systemic therapies and emerging treatments How do I choose a systemic agent? Amy S. Paller, M.D. Walter J. Hamlin Professor and Chair of Dermatology Professor of Pediatrics Northwestern University
More informationDupilumab Efficacy and Safety in Adult Patients With Active Eosinophilic Esophagitis: a Randomized Double-Blind Placebo-Controlled Phase 2 Trial
Dupilumab Efficacy and Safety in Adult Patients With Active Eosinophilic Esophagitis: a Randomized Double-Blind -Controlled Phase 2 Trial Ikuo Hirano, Evan S. Dellon, Jennifer D. Hamilton, Margaret H.
More informationPediatric Inflammatory Skin Disease Update. Inflammatory Skin Diseases. Factors influencing development of atopic dermatitis.
Pediatric Inflammatory Skin Disease Update Lawrence F. Eichenfield, M.D. Professor of Dermatology and Pediatrics Rady Children s Hospital, San Diego University of California, San Diego Disclosure Lawrence
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Dupixent) Reference Number: CP.HNMC.208 Effective Date: 04.11.17 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationItchy babies: Current treatment guidelines for atopic dermatitis
Itchy babies: Current treatment guidelines for atopic dermatitis Rachel Laarman, MD Helen DeVos Children s Hospital Grand Rapids, MI Photo cred: www.dermatologytimes.modernmedicine.com I have no disclosures
More informationRecent insights into atopic dermatitis and implications for management of infectious complications
Mark Boguniewicz, MD Professor, Division of Allergy-Immunology Department of Pediatrics National Jewish Health and University of Colorado School of Medicine Denver, Colorado USA Recent insights into atopic
More informationDupilumab for treating adults with moderate to severe atopic dermatitis [ID1048]
Dupilumab for treating adults with moderate to severe atopic dermatitis [ID1048] Thank you for agreeing to give us your organisation s views on this technology and its possible use in the NHS. You can
More informationMolecular mechanisms in atopic eczema - why do they ma6er in the clinic?
Molecular mechanisms in atopic eczema - why do they ma6er in the clinic? Sara Brown Professor of Molecular & Gene0c Dermatology Wellcome Trust Senior Fellow in Clinical Research Professor of Molecular
More informationNovel Insights in Atopic Dermatitis: Pathways, Biomarkers, and Phenotypes for a Targeted Approach Transcript
Novel Insights in Atopic Dermatitis: Pathways, Biomarkers, and Phenotypes for a Targeted Approach Transcript Title Slide Welcome to the CME-certified program: Novel Insights in Atopic Dermatitis; Pathways,
More informationWhat is atopic dermatitis?
What is atopic dermatitis? Complex inflammatory skin disorder intense pruritus cutaneous hyperreactivity immune dysregulation Chronic with exacerbations and remissions Affects all ages, but more common
More informationSupplementary Online Content
Supplementary Online Content Drury KE, Schaeffer M, Silverberg JI. Association between atopic disease and anemia in US children. JAMA Pediatr. Published online vember 30, 2015. doi:10.1001/jamapediatrics.2015.3065.
More informationBeacon Hospital Annual Study Morning Treatment of Atopic Dermatitis (Eczema) in Primary Care
Beacon Hospital Annual Study Morning Treatment of Atopic Dermatitis (Eczema) in Primary Care Alan D. Irvine MD DSc Lecture overview What causes AD How to get optimise results in primary care Eczema and
More informationAtopic Dermatitis: Clinical Refresh
In this issue: Atopic Dermatitis: Clinical Refresh Asthma Zero Albuterol Refills: 200 Puffs is Enough Safety of Tricyclic Antidepressants in Older Adults Skeletal Muscle Relaxant Quantity Limits FAQ Pharmacy
More informationLead team presentation
Lead team presentation Dupilumab for treating adults with moderate to severe atopic dermatitis [ID1048] 1 st Appraisal Committee meeting Committee B Chair: Amanda Adler Lead team: Diar Fattah, Danielle
More informationDupilumab and Crisaborole for Atopic Dermatitis: Effectiveness, Value, and Value-Based Price Benchmarks
Dupilumab and Crisaborole for Atopic Dermatitis: Effectiveness, Value, and Value-Based Price Benchmarks Draft Background and Scope November 7, 2016 Background: Atopic dermatitis (eczema) is a chronic/chronically-relapsing
More informationThe safety and effectiveness of Dupixent in pediatric patients have not been established (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.30 Subject: Dupixent Page: 1 of 6 Last Review Date: September 15, 2017 Dupixent Description Dupixent
More informationClinical Review Report
CADTH COMMON DRUG REVIEW Clinical Review Report DUPILUMAB (DUPIXENT) (Sanofi-Aventis Canada Inc.) Indication: Moderate-to-severe atopic dermatitis (AD) Service Line: CADTH Common Drug Review Version: Final
More informationDupixent (dupilumab)
Dupixent (dupilumab) Line(s) of Business: HMO; PPO; QUEST Integration Effective Date: TBD POLICY A. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered
More informationHeld in conjunction with AMCP Managed Care & Specialty Pharmacy Annual Meeting Jointly provided by
Jointly provided by This activity is supported by independent educational grants from Sanofi Genzyme and Regeneron Pharmaceuticals Held in conjunction with AMCP Managed Care & Specialty Pharmacy Annual
More informationContact Dermatitis In Atopic Patients
Contact Dermatitis In Atopic Patients Jenny Murase, MD Palo Alto Foundation Medical Group Director of Patch Testing University of California, San Francisco Associate Clinical Professor Disclosures Consultant
More information2.0 Synopsis. Adalimumab R&D/04/118. (For National Authority Use Only) Referring to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
More informationDupilumab and Crisaborole for Atopic Dermatitis: Effectiveness and Value
Dupilumab and Crisaborole for Atopic Dermatitis: Effectiveness and Value Evidence Report May 12, 2017 Prepared for Institute for Clinical and Economic Review, 2017 ICER Staff David M. Rind, MD, MSc Chief
More informationGlenmark Pharmaceuticals Inc., USA; Glenmark Pharmaceuticals Ltd., India. Icahn School of Medicine at Mount Sinai, New York, NY, USA;
RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, EXPLORATORY, MULTICENTER STUDY OF IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS Emma Guttman-Yassky, MD, PhD 1 ; Ana B. Pavel,
More informationAtopic Dermatitis and Primary Immunodeficiency: When Should I Worry?
Atopic Dermatitis and Primary Immunodeficiency: When Should I Worry? Markus Boos, MD PhD Attending Physician, Dermatology Seattle Children s Hospital Assistant Professor of Pediatrics, University of Washington
More informationBiologic Therapy in the Management of Asthma. Nabeel Farooqui, MD
Biologic Therapy in the Management of Asthma Nabeel Farooqui, MD None Disclosures Objectives Define severe asthma phenotypes and endotypes Describe the role of biologics in asthma management Review pivotal
More informationPUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) Elidel 10mg/g cream DATE: , VERSION 12.0
PUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) Elidel 10mg/g cream DATE: 23.11.2016, VERSION 12.0 VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Eczema mainly affects children
More informationPsoriasiform Dermatitis in Children: Calling in the Troops
Psoriasiform Dermatitis in Children: Calling in the Troops Markus Boos, MD PhD Attending Physician, Dermatology Seattle Children s Hospital Assistant Professor of Pediatrics, University of Washington School
More informationCurrent and Future Prospects for the Treatment of Food Allergy
Current and Future Prospects for the Treatment of Food Allergy Robert A. Wood, MD Professor of Pediatrics and International Health Director, Pediatric Allergy and Immunology Director, Pediatric Clinical
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2116-3 Program Prior Authorization/Medical Necessity Medications Dupixent (dupilumab) P&T Approval Date 1/2017, 5/2017, 7/2017
More informationEucrisa. Eucrisa (crisaborole) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Eucrisa Page: 1 of 7 Last Review Date: June 22, 2018 Eucrisa Description Eucrisa (crisaborole)
More informationAllergy, Atopy and Skin Cancer
M. Shane Cahpman, MD, MBA: Dartmouth School of Medicine Boni E. Elewski, MD: University of Alabama Kenneth J. Tomecki, MD: Cleveland Clinic Ted Rosen, MD: Baylor College of Medicine Clinical and Therapeutic
More informationREFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) Executive Summary The below mentioned table presents key metrics for Elidel in the major pharmaceutical markets: the
More informationA Wolf in Sheep s Clothing Cautionary Tales from Eczema Clinic
A Wolf in Sheep s Clothing Cautionary Tales from Eczema Clinic Mark Boguniewicz, MD Professor, Division of Allergy-Immunology Department of Pediatrics National Jewish Health and University of Colorado
More informationThe Treatment Toolbox for Severe Pediatric Psoriasis
The Treatment Toolbox for Severe Pediatric Psoriasis Dr. Kim A. Papp, MD, PhD, FRCPC, FAAD K Papp Clinical Research and Probity Medical Research Objectives: Treating severe pediatric psoriasis 1. Challenges
More informationNew Developments in the Treatment of Atopic Dermatitis: Clinical Highlights From Vienna
CME/MOC New Developments in the Treatment of Atopic Dermatitis: Clinical Highlights From Vienna Course Director Emma Guttman-Yassky, MD, PhD Icahn School of Medicine at Mount Sinai New York, New York What
More informationPediatric Dermatology. Dra. Ana Batalla
Pediatric Dermatology Dra. Ana Batalla Special aspects of skin in neonates and infants Prof. Dr. Regina Fölster-Holst. Kiel - Germany. Vernix caseosa facilitates the development of stratum corneum Functions
More informationWhat have we learned about eczema from routinely-collected health data?
What have we learned about eczema from routinely-collected health data? Sinéad M Langan Wellcome Senior Clinical Fellow London School of Hygiene and Tropical Medicine Why eczema? Observational studies
More informationThe Natural History of Psoriasis and Treatment Goals
The Natural History of Psoriasis and Treatment Goals Psoriasis Epidemiology Prevalence Affects 2 3% of adult population (>7 million in US) Caucasians: 25% 2.5% African Americans: 1.3% (more likely to have
More informationRecalcitrant Warty Erythroderma With Severe Pruritus. Gil Yosipovitch Professor & Chair Department of Dermatology & Itch Center Temple University
Recalcitrant Warty Erythroderma With Severe Pruritus Gil Yosipovitch Professor & Chair Department of Dermatology & Itch Center Temple University DISCLOSURE OF RELEVANT RELATIONSHIPS WITH INDUSTRY Gil Yosipovitch,
More informationeczema the basics 2EE6E629CEA25112ABD0B8EB Eczema The Basics 1 / 6
Eczema The Basics 1 / 6 2 / 6 3 / 6 Eczema The Basics Eczema is a group of conditions that cause inflammation of the skin. Typically, eczema causes skin to become itchy, red, and dry -- even cracked and
More informationEucrisa. Eucrisa (crisaborole) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.25 Subject: Eucrisa Page: 1 of 6 Last Review Date: September 15, 2017 Eucrisa Description Eucrisa
More informationSynopsis (C0743T10) CNTO 1275 Module 5.3 C0743T10. Associated with Module 5.3 of the Dossier
Module 5.3 Protocol: EudraCT No.: 2005-003525-92 Title of the study: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of, a Fully Human Anti-IL-12 Monoclonal Antibody, Administered
More informationBrian S. Kim, MD, MTR, FAAD
What s New In the Pathophysiology of Itch? Brian S. Kim, MD, MTR, FAAD Assistant Professor of Dermatology, Anesthesiology, and Pathology and Immunology Co-Director, Center for the Study of Itch Itch is
More informationBiologics in Asthma: Present and Future
Biologics in Asthma: Present and Future Flavia Hoyte, MD Associate Professor of Medicine Fellowship Training Program Director Division of Allergy and Immunology National Jewish Health and University of
More informationDo We Need Biologics in Pediatric Asthma Management?
Do We Need Biologics in Pediatric Asthma Management? Ting Fan LEUNG, MBChB, MD, FRCPCH, FAAAAI Professor and Chairman Department of Paediatrics The Chinese University of Hong Kong Asthma and Allergy by
More information(LIBERTY AD CHRONOS):
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase
More informationAtopic Dermatitis and Topical Antipsoriatics
Atopic Dermatitis and Topical Antipsoriatics Goal(s): Restrict dermatological drugs only for funded OHP diagnoses. Moderate/severe psoriasis and moderate/severe atopic dermatitis treatments are funded
More informationDermatology elective for yr. 5. Natta Rajatanavin, MD. Div. of dermatology Dep. Of Medicine, Ramathibodi Hospital Mahidol University 23 rd Feb 2015
Dermatology elective for yr. 5 Natta Rajatanavin, MD. Div. of dermatology Dep. Of Medicine, Ramathibodi Hospital Mahidol University 23 rd Feb 2015 How to diagnosis and manage eczema and psoriasis. Objectives
More informationAn Update on Atopic Dermatitis
An Update on Atopic Dermatitis Mark Boguniewicz, MD Professor, Division of Allergy-Immunology Department of Pediatrics National Jewish Health and University of Colorado School of Medicine Disclosures for
More informationPresenter: Tomoko Maeda-Chubachi* Tomoko Maeda-Chubachi, Todd Durham, Stephen Schleicher, Phoebe Rich, Emma Guttman-Yassky
A Topical Nitric Oxide-Releasing Cream SB414: Results of a Phase 1b Double-Blind, Randomized, Vehicle-Controlled Study in Patients with Mild-to- Moderate Atopic Dermatitis Presenter: Tomoko Maeda-Chubachi*
More informationStudy Overview. aafa.org
Study Overview aafa.org This survey was a research project of the Asthma and Allergy Foundation of America in partnership with the National Eczema Association and with support from Sanofi Genzyme and Regeneron.
More informationOmalizumab (Xolair ) ( Genentech, Inc., Novartis Pharmaceuticals Corp.) September Indication
( Genentech, Inc., Novartis Pharmaceuticals Corp.) September 2003 Indication The FDA recently approved Omalizumab on June 20, 2003 for adults and adolescents (12 years of age and above) with moderate to
More informationMedication Policy Manual. Topic: Dupixent, dupilumab Date of Origin: March 10, Committee Approval: March 10, 2017 Next Review Date: May 2018
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Policy No: dru493 Topic: Dupixent, dupilumab Date of Origin: March 10, 2017 Committee Approval: March 10, 2017
More information20/11/55. Food Allergy and Atopic Dermatitis. Outline of Talk - 1. Outline of talk - 2
Food Allergy and Atopic Dermatitis Pakit Vichyanond, MD Department of Pediatrics Faculty of Medicine Siriraj Hospital Mahidol University, Bangkok, Thailand Outline of Talk - 1 Frequency of food sensitization
More informationECZEMA SOCIETY OF CANADA ATOPIC DERMATITIS: PATIENT INSIGHTS REPORT MILD-TO-MODERATE DISEASE
ECZEMA SOCIETY OF CANADA ATOPIC DERMATITIS: PATIENT INSIGHTS REPORT MILD-TO-MODERATE DISEASE 1 OVERVIEW OF SURVEY RESULTS INTRODUCTION PATIENT INSIGHTS BY THE NUMBERS: Adult Atopic Dermatitis (AD) In the
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (dupilumab) injection, for subcutaneous
More informationAtopic Dermatitis: Therapeutic Challenges
Atopic Dermatitis: Therapeutic Challenges PDA August 14, 2009 Jon Hanifin OHSU, Portland Dominant Concepts in Atopic Dermatitis Allergy / Immunology Era: 1915-2006 The Epidermal Era: 2006---- Barrier dysfunction
More informationNovan Provides Update on SB414 Inflammatory Skin Disease Development Program
Novan Provides Update on SB414 Inflammatory Skin Disease Development Program SB414 Nitric Oxide-Releasing Cream Safe and Well-Tolerated in Psoriasis Phase 1b Trial Preclinical Data with SB414 Targeting
More informationMalignancy Risk in Pediatric IBD: What to tell parents and patients?
Malignancy Risk in Pediatric IBD: What to tell parents and patients? Corey A. Siegel, MD, MS Geisel School of Medicine at Dartmouth Dartmouth-Hitchcock Medical Center Digestive Disease Week 2017 Chicago,
More informationREFERENCE CODE GDHC294DFR PUBLICATION DATE NOVEMBER 2013 PROTOPIC (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC294DFR PUBLICATION DATE NOVEMBER 2013 PROTOPIC (ATOPIC DERMATITIS) Executive Summary The below mentioned table presents key metrics for Protopic in the nine major pharmaceutical markets
More informationImmunotherapy for Food Allergy: Is it Ready for Primetime?
Immunotherapy for Food Allergy: Is it Ready for Primetime? Bruce J. Lanser, MD Assistant Professor of Pediatrics Director, National Jewish Health Pediatric Food Allergy Center Associate Director, Pediatric
More information2/25/17. Translating the Evidence: Allergy vs. Dermatology. How can they disagree?! Bias: It doesn t come out in the wash. wash. Precision Medicine
Translating the Evidence: Allergy vs. Dermatology Peter A. Lio, MD, FAAD Assistant Professor Clinical Dermatology & Pediatrics Northwestern University Feinberg School of Medicine How can they disagree?!
More informationISAAC Global epidemiology of allergic diseases. Innes Asher on behalf of the ISAAC Study Group 28 November 2009
ISAAC Global epidemiology of allergic diseases Innes Asher on behalf of the ISAAC Study Group 28 November 2009 http://isaac.auckland.ac.nz The challenge A fresh look was needed with a world population
More informationWYNNIS L. TOM, MD: And I m Dr. Wynnis Tom. I m Associate Professor of Dermatology and Pediatrics at the University of California, San Diego.
LEARNING OBJECTIVES At the conclusion of this activity, participants should be better able to: Assess the severity of atopic dermatitis (AD) and its impact on the patient Evaluate treatment efficacy Design
More informationDUPIXENT FDA Approval Call March 28, 2017
DUPIXENT FDA Approval Call March 28, 2017 1 Sanofi Forward Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 GRAZAX 75 000 SQ-T, oral lyophilisate B/30 (CIP: 378 011-6) B/100 (CIP code: 378 012-2) B/90 (CIP code:
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION DUPIXENT. dupilumab. solution for subcutaneous injection. 150 mg/ml
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr DUPIXENT dupilumab solution for subcutaneous injection 150 mg/ml Immunomodulator, Interleukin inhibitor Sanofi-aventis Canada Inc. 2905 Place
More informationAnti-IgE: beyond asthma
Anti-IgE: beyond asthma Yehia El-Gamal, MD, PhD, FAAAAI Professor of Pediatrics Pediatric Allergy and Immunology Unit Children s Hospital, Ain Shams University Member, WAO Board of Directors Disclosure
More informationTopical Immunomodulator Step Therapy Program
Topical Immunomodulator Step Therapy Program Policy Number: 5.01.557 Last Review: 8/2017 Origination: 7/2013 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) BCBSKC will provide
More informationRisk = probability x consequence
Explaining Risks of IBD Therapy to Parents and Patients December 4, 2009 CCFA Advances in IBD Hollywood, FL Corey A. Siegel Assistant Professor of Medicine, Dartmouth Medical School Director, Dartmouth-Hitchcock
More information2.0 Synopsis. Adalimumab M Clinical Study Report R&D/04/900. (For National Authority Use Only) Referring to Part of Dossier: Volume:
2. Synopsis Abbott Laboratories Name of Study Drug: Name of Active Ingredient: Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Phase
More informationTwo Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
The new england journal of medicine Original Article Two Phase 3 Trials of versus in Atopic Dermatitis E.L. Simpson, T. Bieber, E. Guttman Yassky, L.A. Beck, A. Blauvelt, M.J. Cork, J.I. Silverberg, M.
More informationThe Skinny of the Immune System
The Skinny of the Immune System Robert Hostoffer, DO, FACOP, FAAP Associate Professor of Pediatrics Case Western Reserve University, Cleveland, Ohio Overview 1. Immune system of the skin 2. Immune Players
More informationBiologics in asthma Are we turning the corner? Roland Buhl Pulmonary Department Mainz University Hospital
Biologics in asthma Are we turning the corner? Roland Buhl Pulmonary Department Mainz University Hospital Biologics in asthma - are we turning the corner? Allergic asthma anti - IgE Allergic airway inflammation
More informationSummary of Risk Minimization Measures
Table 6.1.4-1: Summary of Risk Minimization Measures Safety Concern Vaccination Hepatic and renal impairment Combination therapy Elderly Routine Risk Minimization Measures Specific subsection on vaccination
More information6/19/18. Emerging Challenges in Primary Care: Atopic Dermatitis: New Insights, New Therapies. Faculty. Disclosures
Emerging Challenges in Primary Care: 2018 Atopic Dermatitis: New Insights, New Therapies 1 Faculty Brad P. Glick, DO, MPH, FAOCD Director, South Florida Psoriasis Treatment Centers Clinical Assistant Professor
More informationHelp! What s the Answer? FRM F027 - Translating Evidence into Practice: Atopic Dermatitis Guidelines
Help! What s the Answer? FRM F027 - Translating Evidence into Practice: Atopic Dermatitis Guidelines Christine T. Lauren, M.D. Assistant Professor of Dermatology and Pediatrics Columbia University, New
More information